reported an HER2 aptamer‐targeted DNA‐NS for lysosomal degradation of tumor‐specific protein molecules and apoptosis by selectively targeting HER2 positive breast cancer.[121] This was achieved by anchoring anti‐HER2 aptamers onto the exterior DNA‐NS resulting in prolonged circulation, higher stability, and improved performance in vivo compared to the free anti‐HER2 aptamer. This evidence concerns the gene ERBB2 and neoplasm.